The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

Founded Year



Acquired | Acquired

Total Raised




About Bamboo Therapeutics

Bamboo Therapeutics is an early-stage biotechnology company dedicated to developing gene therapies for orphan diseases. The gene therapy, initially called BMB-D001, has shown positive effects in Duchenne animal models including improved life span as well as skeletal and cardiac muscle function in both mice and rats.

Bamboo Therapeutics Headquarter Location

870 Martin Luther King Jr Blvd.

Chapel Hill, North Carolina, 27514,

United States


Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Bamboo Therapeutics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Bamboo Therapeutics is included in 1 Expert Collection, including Regenerative Medicine.


Regenerative Medicine

1,818 items

Regenerative medicine refers to the process of activating, replacing, engineering or regenerating human genetic material, cells, tissues or organs to restore normal function. It also includes bioengineered tissues used for in vitro testing (e.g. organ-on-a-chip, organoids).

Bamboo Therapeutics Patents

Bamboo Therapeutics has filed 4 patents.

The 3 most popular patent topics include:

  • Molecular biology
  • Biotechnology
  • Genetics
patents chart

Application Date

Grant Date


Related Topics




Rare diseases, Autosomal recessive disorders, Molecular biology, Neurological disorders, Syndromes


Application Date


Grant Date



Related Topics

Rare diseases, Autosomal recessive disorders, Molecular biology, Neurological disorders, Syndromes



Latest Bamboo Therapeutics News

Pfizer pauses Duchenne gene therapy trial after patient death

Dec 22, 2021

December 22, 2021 Pfizer has called a halt to a clinical trial of its gene therapy for Duchenne muscular dystrophy as it investigates the unexpected death of a young male patient. In an update posted today the pharma giant said “we do not yet have complete information and are actively working with the trial site investigator to understand what happened.” In the meantime, it is pausing screening and dosing of the fordadistrogene movaparvovec (PF-06939926) gene therapy, and working with the trial’s data monitoring committee to try to establish whether the death is related to the drug. “The safety and well-being of the patients in our clinical trial remains our top priority, and we are committed to sharing more information with the medical and patient community as soon as we can,” said the letter. The pause – which has been accompanied by a clinical hold imposed by the FDA – applies to a phase 1b trial that was testing the ability of the adeno-associated virus (AAV) based therapy to deliver and express  a truncated version of the gene coding for dystrophin, a protein which is deficient in DMD. AAV vectors are well-suited to gene therapies for DMD because they are effective at targeting muscle tissue. The death was seen in a patient in the non-ambulatory arm of the study, which involves patients who are more severely affected by the muscle wasting disease. Pfizer added the gene therapy to its pipeline in 2016, when it acquired Bamboo Therapeutics in a deal worth up to $645 million. The safety of gene therapies has been in the spotlight in the past few years, with several therapies using AAV as well as other viral vectors placed on hold by regulators while potential side effects are investigated. There has been speculation that the AAV vectors may activate the complement system, leading to inflammation in tissues. Pfizer’s two closest rivals in the DMD gene therapy space – Sarepta and Solid Biosciences – have both had their AAV-based gene therapies for DMD temporarily placed on clinical hold in the past, but were able to restart testing. Pfizer meanwhile has had other scares about the safety of its gene therapy, including most recently reports of muscle weakness and myocarditis in some patients who received the gene therapy, which seem to be linked to certain genetic mutations affecting exons 9 to 13, and 29 and 30. Its pivotal CIFFREO trial – which is being conducted in ambulatory patients who are able to walk – has been modified to exclude patients with these mutations, and at the moment it is unclear whether it will be affected by the clinical hold. Recruitment into CIFFREO in the US has been delayed in the US by an FDA request for potency, but is already underway elsewhere, including in Europe and Asia. Pfizer has been talking about having interim data from the trial in the third quarter of next year. Sarepta meanwhile is running the EMBARK phase 3 study of SRP-9001, and expects to fully enrol the trial in the first half oof 2022. Solid Bio said recently it has started dosing additional patients in its phase 1/2 trial of SGT-001 – called IGNITE DMD – and will have further results from the first three patients treated with the therapy next year. Don't miss your daily pharmaphorum news.

  • When was Bamboo Therapeutics founded?

    Bamboo Therapeutics was founded in 2014.

  • Where is Bamboo Therapeutics's headquarters?

    Bamboo Therapeutics's headquarters is located at 870 Martin Luther King Jr Blvd., Chapel Hill.

  • What is Bamboo Therapeutics's latest funding round?

    Bamboo Therapeutics's latest funding round is Acquired.

  • How much did Bamboo Therapeutics raise?

    Bamboo Therapeutics raised a total of $49.47M.

  • Who are the investors of Bamboo Therapeutics?

    Investors of Bamboo Therapeutics include Pfizer and CureDuchenne Ventures.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.